Insomnia, hypnotic use, and health-related quality of life in a nationally representative sample

Quality of Life Research

Volumn 24, Issue 5, 2015, Pages 1223-1233

  Scalo, Julieta ^a   Desai, Pooja ^a   Rascati, Karen ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Health related quality of life; Hypnotic; Insomnia; MEPS; SF 12; Sleep

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; BENZODIAZEPINE DERIVATIVE; HYPNOTIC SEDATIVE AGENT;

ADULT; AGED; DRUG EFFECTS; FEMALE; HEALTH STATUS; HEALTH SURVEY; HUMAN; MALE; MIDDLE AGED; PHYSIOLOGY; PRESCRIPTION; PSYCHOLOGY; QUALITY OF LIFE; RETROSPECTIVE STUDY; SLEEP; SLEEP INITIATION AND MAINTENANCE DISORDERS; SOCIAL CLASS;

ADULT; AGED; BENZODIAZEPINES; DRUG PRESCRIPTIONS; FEMALE; GABA-A RECEPTOR AGONISTS; HEALTH STATUS; HEALTH SURVEYS; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MIDDLE AGED; QUALITY OF LIFE; RETROSPECTIVE STUDIES; SLEEP; SLEEP INITIATION AND MAINTENANCE DISORDERS; SOCIAL CLASS;

EID: 84938079309     PISSN: 09629343     EISSN: 15732649     Source Type: Journal    
DOI: 10.1007/s11136-014-0842-1     Document Type: Article

References (70)

1. Léger, D., & Poursain, B. (2005). An international survey of insomnia: Under-recognition and under-treatment of a polysymptomatic condition. Current Medical Research and Opinion,21, 1785–1792.
2. Morin, C. M., LeBlanc, M., Daley, M., Gregoire, J. P., & Mérette, C. (2006). Epidemiology of insomnia: Prevalence, self-help treatments, consultations, and determinants of help-seeking behaviors. Sleep Medicine,7, 123–130.
3. Stepanski, E., Koshorek, G., Zorick, F., Glinn, M., & Roehrs, T. (1989). Characteristics of individuals who do or do not seek treatment for chronic insomnia. Psychosomatics, 30(4), 421–427. doi:10.1016/S0033-3182(89)72248-9.
4. Roth, T., Coulouvrat, C., Hajak, G., Lakoma, M. D., Sampson, N. A., Shahly, V., et al. (2011). Prevalence and perceived health associated with insomnia based on DSM-IV-TR; International Statistical Classification of Diseases and Related Health Problems, Tenth Revision; and Research Diagnostic Criteria/International Classification of Sleep Disorders, Second Edition Criteria: Results from the America Insomnia Survey. Biological Psychiatry,69, 592–600.
5. Léger, D., Morin, C. M., Uchiyama, M., Hakimi, Z., Cure, S. S., & Walsh, J. K. (2012). Chronic insomnia, quality-of-life, and utility scores: Comparison with good sleepers in a cross-sectional international survey. Sleep Medicine,13, 43–51.
6. Komada, Y., Nomura, T., Kusumi, M., Nakashima, K., Okajima, I., Sasai, T., et al. (2012). A two-year follow-up study on the symptoms of sleep disturbances/insomnia and their effects on daytime functioning. Sleep Medicine,13, 1115–1121.
7. Sasai, T., Inoue, Y., Komada, Y., Nomura, T., Matsuura, M., & Matsushima, E. (2010). Effects of insomnia and sleep medication on health-related quality of life. Sleep Medicine,11, 6.
8. Lee, M., Choh, A. C., Demerath, E. W., Knutson, K. L., Duren, D. L., Sherwood, R. J., et al. (2009). Sleep disturbance in relation to health-related quality of life in adults: The Fels Longitudinal Study. The Journal of Nutrition, Health and Aging,13, 576–583.
9. Bolge, S. C., Doan, J. F., Kannan, H., & Baran, R. W. (2009). Association of insomnia with quality of life, work productivity, and activity impairment. Quality of Life Research,18, 415–422.
10. LeBlanc, M., Beaulieu-Bonneau, S., Mérette, C., Savard, J., & Ivers, H. (2007). Morin CM: Psychological and health-related quality of life factors associated with insomnia in a population-based sample. Journal of Psychosomatic Research,63, 157–166.
11. Schubert, C. R., Cruickshanks, K. J., Dalton, D. S., Klein, B. E. K., Klein, R., & Nondahl, D. M. (2002). Prevalence of sleep problems and quality of life in an older population. Sleep,25, 889–893.
12. Katz, D. A., & McHorney, C. A. (2002). The relationship between insomnia and health-related quality of life in patients with chronic illness. Journal of Family Practice,51, 229–235.
13. Buysse, D. J., Ancoli-Israel, S., Edinger, J. D., Lichstein, K. L., & Morin, C. M. (2006). Recommendations for a standard research assessment of insomnia. Sleep,29, 1155–1173.
14. Krystal, A. D. (2007). Treating the health, quality of life, and functional impairments in insomnia. Journal of Clinical Sleep Medicine,3, 63–72.
15. Kyle, S. D., Morgan, K., & Espie, C. A. (2010). Insomnia and health-related quality of life. Sleep Medicine Reviews,14, 69–82.
16. Ishak, W. W., Bagot, K., Thomas, S., Magakian, N., Bedwani, D., Larson, D., et al. (2012). Quality of life in patients suffering from insomnia. Innovations in Clinical Neuroscience,9, 13–26.
17. Hajak, G., Rodenbeck, A., Voderholzer, U., Riemann, D., Cohrs, S., Hohagen, F., et al. (2001). Doxepin in the treatment of primary insomnia: A placebo-controlled, double-blind, polysomnographic study. Journal of Clinical Psychiatry,62, 453–463.
18. Krystal, A. D., Walsh, J. K., Laska, E., Caron, J., Amato, D. A., Wessel, T. C., et al. (2003). Sustained efficacy of eszopiclone over 6 months of nightly treatment: Results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep,26, 793–799.
19. Asnis, G. M., Chakraburtty, A., DuBoff, E. A., Krystal, A. D., Londborg, P. D., Rosenberg, R., et al. (1999). Zolpidem for persistent insomnia in SSRI-treated depressed patients. Journal of Clinical Psychiatry,60, 668–676.
20. Walsh, J. K., Roth, T., Randazzo, A., Erman, M., Jamieson, A., Scharf, M., et al. (2000). Eight weeks of non-nightly use of zolpidem for primary insomnia. Sleep,23, 1087–1096.
21. Lader, M. (2011). Benzodiazepines revisited—will we ever learn? Addiction,106, 2086–2109.
22. Bertisch, S. M., Herzig, S. J., Winkelman, J. W., & Buettner, C. (2014). National use of prescription medications for insomnia: NHANES 1999–2010. Sleep,37, 343–349.
23. Stahl, S. M. (2002). Selective actions on sleep or anxiety by exploiting GABA-A/benzodiazepine receptor subtypes. Journal of Clinical Psychiatry,63, 179–180.
24. McCall, C., & McCall, W. V. (2012). What is the role of sedating antidepressants, antipsychotics, and anticonvulsants in the management of insomnia? Current Psychiatry Reports,14, 494–502.
25. Medical Expenditure Panel Survey: Survey Overview: Slide Presentation from the AHRQ 2008 Annual Conference (Text Version). http://www.ahrq.gov/about/annualmtg08/091008slides/MoyBattles.htm
26. Medical Expenditure Panel Survey. http://www.meps.ahrq.gov/mepsweb/
27. MEPS HC-036: 1996–2007 pooled estimation file. http://meps.ahrq.gov/mepsweb/data_stats/download_data/pufs/h36/h36u07doc.shtml
28. Gandek, B. (1998). Overview of the SF-36 health survey and the international quality of life assessment (IQOLA) project. Journal of Clinical Epidemiology,51, 903–912.
29. Ware, J. E., Jr., Kosinski, M., & Keller, S. D. (1996). A 12-item short-form health survey: Construction of scales and preliminary tests of reliability and validity. Medical Care,34, 220–233.
30. Léger, D., Scheuermaier, K., Paillard, M., & Guilleminault, C. (2001). SF-36: Evaluation of quality of life in severe and mild insomniacs compared with good sleepers. Psychosomatic Medicine,63, 49–55.
31. Le Guen, Y., Gagnadoux, F., Hureaux, J., Jeanfaivre, T., Meslier, N., Racineux, J. L., & Urban, T. (2007). Sleep disturbances and impaired daytime functioning in outpatients with newly diagnosed lung cancer. Lung Cancer, 58(1), 139–143. doi:10.1016/j.lungcan.2007.05.021.
32. Vena, C. I., Parker, K. P., Allen, R., Bliwise, D. L., & Kimble, L. (2007). Sleep-wake disturbances and quality of life in patients with advanced lung cancer. Oncology Nursing Forum,33, 761–769.
33. Tsilika, E., Gennatas, C., Galanos, A., & Vlahos, L. (2008). How is sleep quality affected by the psychological and symptom distress of advanced cancer patients? Palliative Medicine,23, 46–53.
34. Cheak-Zamora, N. C., Wyrwich, K. W., & McBride, T. D. (2009). Reliability and validity of the SF-12v2 in the medical expenditure panel survey. Quality of Life Research,18, 727–735.
35. Norman, G. R., Sloan, J. A., & Wyrwich, K. W. (2003). Interpretation of changes in health-related quality of life: The remarkable universality of half a standard deviation. Medical Care, 41(5), 582–592. doi:10.1097/01.MLR.0000062554.74615.4C.
36. Cohen, J. (1992). A power primer. Psychological Bulletin,112, 155–159.
37. D’Hoore, W., Bouckaert, A., & Tilquin, C. (1996). Practical considerations on the use of the Charlson comorbidity index with administrative data bases. Journal of Clinical Epidemiology,49, 1429–1433.
38. Charlson, M., Szatrowski, T. P., & Peterson, J. (1994). Validation of a combined comorbidity index. Journal of Clinical Epidemiology, 47(11), 1245–1251. doi:10.1016/0895-4356(94)90129-5.
39. Bootzin, R. R., & Epstein, D. R. (2011). Understanding and treating insomnia. Annual Review of Clinical Psychology,7, 435–458.
40. Meissner, H. H., Riemer, A., Santiago, S. M., Stein, M., Goldman, M. D., & Williams, A. J. (1998). Failure of physician documentation of sleep complaints in hospitalized patients. Western Journal of Medicine,169, 146–149.
41. Zisapel, N. (2012). Drugs for insomnia. Expert Opinion on Emerging Drugs,17, 299–317.
42. Rosen, R. C., Zozula, R., Jahn, E. G., & Carson, J. L. (2001). Low rates of recognition of sleep disorders in primary care: Comparison of a community-based versus clinical academic setting. Journal of Chronic Diseases,2, 47–55.
43. Senthilvel, E., Auckley, D., & Dasarathy, J. (2011). Evaluation of sleep disorders in the primary care setting: History taking compared to questionnaires. Journal of Clinical Sleep Medicine,7, 41–48.
44. Morlock, R. J., Tan, M., & Mitchell, D. Y. (2006). Patient characteristics and patterns of drug use for sleep complaints in the United States: Analysis of National Ambulatory Medical Survey data, 1997–2002. Clinical Therapeutics,28, 1044–1053.
45. Lai, L. L., Tan, M. H., & Lai, Y. C. (2011). Prevalence and factors associated with off-label antidepressant prescriptions for insomnia. DHPS,3, 27–36.
46. Roehrs, T., & Roth, T. (2004). “Hypnotic” prescription patterns in a large managed-care population. Sleep Medicine,5, 463–466.
47. Pawaskar, M. D., Joish, V. N., Camacho, F. T., Rasu, R. S., & Balkrishnan, R. (2008). The influence of co-morbidities on prescribing pharmacotherapy for insomnia: Evidence from US national outpatient data 1995–2004. Journal of Medical Economics,11, 41–56.
48. Ohayon, M. M. (2002). Epidemiology of insomnia: What we know and what we still need to learn. Sleep Medicine Reviews,6, 15.
49. Ohayon, M. M., & Roth, T. (2001). What are the contributing factors for insomnia in the general population? Journal of Psychosomatic Research,51, 745–755.
50. Swanson, L. M., Arnedt, J. T., Rosekind, M. R., Belenky, G., Balkin, T. J., & Drake, C. L. (2011). Sleep disorders and work performance: Findings from the 2008 National Sleep Foundation Sleep in America poll. Journal of Sleep Research,20, 487–494.
51. Ozminkowski, R. J., Wang, S., & Walsh, J. K. (2007). The direct and indirect costs of untreated insomnia in adults in the United States. Sleep,30, 263–273.
52. Buysse, D. J., Grunstein, R. R., Horne, J. J., & Lavie, P. P. (2010). Can an improvement in sleep positively impact on health? Sleep Medicine Reviews,14(6), 405–410. doi:10.1016/j.smrv.2010.02.001.
53. Rombaut, N., Maillard, F., & Kelly, F. (1990). The quality of life of insomniacs questionnaire (QOLI). Medical Science Research,18, 845–847.
54. Léger, D., Scheuermaier, K., Raffray, T., Metlaine, A., Choudat, D., & Guilleminault, C. (2005). HD-16: A new quality of life instrument specifically designed for insomnia. Sleep Medicine,6, 191–198.
55. Kyle, S. D., Crawford, M. R., Morgan, K., Spiegelhalder, K., Clark, A. A., & Espie, C. A. (2013). The Glasgow Sleep Impact Index (GSII): A novel patient-centred measure for assessing sleep-related quality of life impairment in Insomnia Disorder. Sleep Medicine,14, 493–501.
56. Morgan, K., Dixon, S., Mathers, N., Thompson, J., & Tomeny, M. (2003). Psychological treatment for insomnia in the management of long-term hypnotic drug use: A pragmatic randomised controlled trial. British Journal of General Practice, 53(497), 923–928.
57. Espie, C. A., MacMahon, K. M. A., Kelly, H.-L., Broomfield, N. M., Douglas, N. J., Engleman, H. M., et al. (2007). Randomized clinical effectiveness trial of nurse-administered small-group cognitive behavior therapy for persistent insomnia in general practice. Sleep,30, 574–584.
58. Soeffing, J. P., Lichstein, K. L., Nau, S. D., McCrae, C. S., Wilson, N. M., Aguillard, R. N., et al. (2008). Psychological treatment of insomnia in hypnotic-dependant older adults. Sleep Medicine,9, 165–171.
59. Morin, C. M., Koetter, U., Bastien, C. H., Ware, J. C., & Wooten, V. (2005). Valerian-hops combination and diphenhydramine for treating insomnia: a randomized placebo-controlled clinical trial. Sleep,28, 1465–1471.
60. McCall, W. V., Erman, M., Krystal, A. D., Rosenberg, R., Scharf, M. M., Zammit, G. K., et al. (2006). A polysomnography study of eszopiclone in elderly patients with insomnia. Current Medical Research and Opinion,22, 1633–1642.
61. Wagner, J., & Wagner, M. (2000). Non-benzodiazepines for the treatment of insomnia. Sleep Medicine Reviews,4, 31.
62. Gunja, N. (2013). The clinical and forensic toxicology of Z-drugs. Journal of Medical Toxicology,9, 155–162.
63. Gunja, N. (2013). In the Zzz zone: The effects of Z-drugs on human performance and driving. Journal of Medical Toxicology,9, 163–171.
64. Drug Safety and Availability—FDA Drug Safety Communication: Risk of next-morning impairment after use of insomnia drugs; FDA requires lower recommended doses for certain drugs containing zolpidem (Ambien, Ambien CR, Edluar, and Zolpimist). http://www.fda.gov/drugs/drugsafety/ucm334033.htm
65. Eisen, J., MacFarlane, J., & Shapiro, C. M. (1993). Psychotropic drugs and sleep. BMJ,306, 1331–1334.
66. Roehrs, T., & Roth, T. (2010). Drug-related sleep stage changes: Functional significance and clinical relevance. Sleep Medicine Clinics,5, 559–570.
67. Tobler, I., Kopp, C., Deboer, T., & Rudolph, U. (2001). Diazepam-induced changes in sleep: Role of the alpha 1 GABA(A) receptor subtype. Proceedings of the National Academic Science Unite States of America,98, 6464–6469.
68. Zisapel, N. (2007). Sleep and sleep disturbances: Biological basis and clinical implications. Cellular and Molecular Life Sciences,64, 1174–1186.
69. Johnson, A. E., & Sanchez, M. E. (1993). Household and medical provider reports on medical conditions: National medical expenditure survey, 1987. Journal of Economic and Social Measurement, 19, 199–223.
70. Zuvekas, S. H., & Olin, G. L. (2009) Validating household reports of health care use in the medical expenditure panel survey. Health Services Research, 44(5p1), 1679–1700.